Modality
Small Molecule
MOA
CAR-T CD19
Target
PRMT5
Pathway
PI3K/AKT
PSP
Development Pipeline
Preclinical
~Feb 2016
→ ~May 2017
Phase 1
~Aug 2017
→ ~Nov 2018
Phase 2
~Feb 2019
→ ~May 2020
Phase 3
~Aug 2020
→ ~Nov 2021
NDA/BLA
Feb 2022
→ Nov 2027
NDA/BLACurrent
NCT07443816
2,041 pts·PSP
2022-02→2027-11·Recruiting
2,041 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-111.6y awayPh3 Readout· PSP
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2027-11-11 · 1.6y away
PSP
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07443816 | NDA/BLA | PSP | Recruiting | 2041 | ORR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Nirarelsin | Johnson & Johnson | Phase 2 | PRMT5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| MRK-853 | Merck & Co | Phase 1 | PRMT5 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| Geliderotide | Sanofi | Phase 1/2 | PRMT5 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-9615 | Novo Nordisk | Phase 2/3 | PRMT5 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| GIL-2259 | Gilead Sciences | Approved | SMN2 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 |